Last reviewed · How we verify
transamin
transamin is a Small molecule drug developed by Erzincan Military Hospital. It is currently in Phase 3 development for Contraception, Endometriosis, Female hypogonadism syndrome.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from various conditions, including surgery, trauma, and heavy menstruation. It works by inhibiting plasminogen, a protein involved in blood clotting, and is typically taken orally, by injection into a vein, or by intramuscular injection.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Rare-disease pathway favourability
+5.0pp
Rare-disease drugs benefit from FDA Orphan Drug Act, smaller pivotal trials, and more flexible endpoints. Approval rates run ~5pp above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | transamin |
|---|---|
| Sponsor | Erzincan Military Hospital |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Rare Disease |
| Phase | Phase 3 |
Approved indications
- Contraception
- Endometriosis
- Female hypogonadism syndrome
- Hemorrhaging in Hemophilia
- Menorrhagia
Common side effects
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion (NA)
- Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty (NA)
- Prevention of Postpartum Hemorrhage With Tranexamic Acid (PHASE2)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transamin CI brief — competitive landscape report
- transamin updates RSS · CI watch RSS
- Erzincan Military Hospital portfolio CI
Frequently asked questions about transamin
What is transamin?
What is transamin used for?
Who makes transamin?
What development phase is transamin in?
What does transamin target?
Related
- Target: All drugs targeting Plasminogen
- Manufacturer: Erzincan Military Hospital — full pipeline
- Therapeutic area: All drugs in Rare Disease
- Indication: Drugs for Contraception
- Indication: Drugs for Endometriosis
- Indication: Drugs for Female hypogonadism syndrome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing